Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lulu C Bravo

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Human Vaccines & Immunotherapeutics|November 27, 2019
Translating science into actionLulu C Bravo
The Southeast Asian Journal of Tropical Medicine and Public Health|October 20, 2012
Etiology, incidence and outcomes of acute hepatic failure in 0-18 year old Filipino childrenLulu C Bravo, Germana V Gregorio, Fakrudeen Shafi, et al.
The New England Journal of Medicine|October 13, 2021
Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in ChildrenTerence Nolan, Alexandre C Fortanier, Brett Leav, et al.
Vaccine|November 10, 2019
Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of ageLulu C Bravo, Josefina C Carlos, Salvacion R Gatchalian, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Human Vaccines & Immunotherapeutics|November 27, 2019
Translating science into actionLulu C Bravo
The Southeast Asian Journal of Tropical Medicine and Public Health|October 20, 2012
Etiology, incidence and outcomes of acute hepatic failure in 0-18 year old Filipino childrenLulu C Bravo, Germana V Gregorio, Fakrudeen Shafi, et al.
The New England Journal of Medicine|October 13, 2021
Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in ChildrenTerence Nolan, Alexandre C Fortanier, Brett Leav, et al.
Vaccine|November 10, 2019
Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of ageLulu C Bravo, Josefina C Carlos, Salvacion R Gatchalian, et al.
Pageof 1